Table 3.
Univariate and Multivariate Analyses of the Prognostic Factors for Overall Survival and Progression-Free Survival
| Characteristics | Overall Survival | Progression-Free Survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||||||
| HR | 95 CI% | P | HR | 95 CI% | P | HR | 95 CI% | P | HR | 95 CI% | P | |
| Age in years (>50 vs ≤50) | 0.655 | 0.283–1.519 | 0.324 | 0.844 | 0.470–1.515 | 0.570 | ||||||
| Gender (Female vs Male) | 0.045 | 0.000–173.11 | 0.462 | 1.303 | 0.466–3.648 | 0.614 | ||||||
| ECOG PS (1 vs 0) | 0.413 | 0.150–1.135 | 0.086 | 0.419 | 0.202–0.872 | 0.020 | 0.350 | 0.151–0.808 | 0.014 | |||
| AFP (>400 vs ≤400 ng/mL) | 1.280 | 0.584–2.807 | 0.538 | 1.426 | 0.801–2.538 | 0.227 | ||||||
| HBV (positive vs negative) | 1.421 | 0.329–6.149 | 0.638 | 1.572 | 0.563–4.388 | 0.388 | ||||||
| Maximum diameter (>10 vs ≤10 cm) | 0.727 | 0.323–1.634 | 0.440 | 0.771 | 0.414–1.435 | 0.412 | ||||||
| BCLC stage (A vs B and C) | 1.892 | 0.809–4.425 | 0.141 | 1.595 | 0.858–2.963 | 0.140 | ||||||
| Vascular invasion (present vs absent) | 1.875 | 0.863–4.074 | 0.112 | 1.626 | 0.924–2.860 | 0.092 | ||||||
| LN metastasis (present vs absent) | 1.625 | 0.660–4.001 | 0.291 | 1.222 | 0.631–2.366 | 0.551 | ||||||
| Distant metastasis (present vs absent) | 3.673 | 1.581–8.536 | 0.002 | 2.195 | 0.852–5.651 | 0.103 | 2.119 | 1.042–4.310 | 0.038 | 3.405 | 1.600– 0.242 | 0.001 |
| Tumor number (multiple vs single) | 4.412 | 1.300–14.969 | 0.017 | 7.023 | 1.332–37.020 | 0.022 | 2.506 | 1.248–5.032 | 0.010 | 2.147 | 0.985–4.681 | 0.055 |
| Tumor distribution (bilobar vs unilobar) | 3.166 | 1.273–7.871 | 0.013 | 1.929 | 0.696–5.341 | 0.206 | 2.073 | 1.135–3.787 | 0.018 | 1.331 | 0.675–2.626 | 0.410 |
| Cirrhosis (present vs absent) | 1.508 | 0.654–3.477 | 0.336 | 1.067 | 0.543–2.098 | 0.851 | ||||||
| Cycles of HAIC (>4 vs ≤4) | 0.653 | 0.288–1.482 | 0.308 | 0.608 | 0.324–1.142 | 0.122 | ||||||
| Chemotherapeutic dose (reduced vs full) | 1.530 | 0.707–3.311 | 0.280 | 1.046 | 0.598–1.830 | 0.875 | ||||||
| 5-FU infusion time in hour (46 vs 23) | 0.627 | 0.252–1.562 | 0.316 | 0.717 | 0.372–1.382 | 0.320 | ||||||
| DEB-TACE times (≥2 vs.1) | 0.266 | 0.079–0.900 | 0.033 | 0.325 | 0.075–1.410 | 0.133 | 0.675 | 0.367–1.244 | 0.208 | |||
| ALT (>40 vs ≤40 U/mL) | 1.067 | 0.484–2.351 | 0.873 | 2.076 | 1.049–4.108 | 0.036 | 2.390 | 1.176–4.858 | 0.016 | |||
| ALB (>40 vs ≤40 g/L) | 0.567 | 0.266–1.212 | 0.143 | 0.882 | 0.504–1.545 | 0.661 | ||||||
| TBIL (>20.5 vs ≤20.5 µmol/L) | 1.122 | 0.444–2.839 | 0.808 | 0.829 | 0.438–1.568 | 0.564 | ||||||
| CRE (>75 vs ≤75 μmol/L) | 1.756 | 0.778–3.964 | 0.175 | 0.785 | 0.436–1.412 | 0.419 | ||||||
| HAIC response (yes vs no, RECIST) | 0.948 | 0.432–2.078 | 0.894 | 1.074 | 0.603–1.911 | 0.808 | ||||||
| HAIC response (yes vs no, mRECIST) | 0.988 | 0.365–2.677 | 0.981 | 1.101 | 0.572–2.122 | 0.773 | ||||||
| DEB-TACE response (yes vs no, RECIST) | 0.467 | 0.062–3.524 | 0.460 | 0.625 | 0.244–1.599 | 0.327 | ||||||
| DEB-TACE response (yes vs no, mRECIST) | 0.347 | 0.136–0.887 | 0.027 | 0.348 | 0.133–0.914 | 0.032 | 0.456 | 0.240–0.864 | 0.016 | 0.386 | 0.197–0.759 | 0.006 |
Note: Statistical significances are marked in bold.
Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; AFP, alpha-fetoprotein; HBV, hepatitis B virus; BCLC, Barcelona Clinic Liver Cancer; LN, lymph node; HAIC, hepatic artery infusion chemotherapy; DEB-TACE, drug-eluting bead transarterial chemoembolization; ALT, alanine transaminase; ALB, albumin; TBIL, total bilirubin; CRE, creatinine; RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST.